Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Spontaneous cervical epidural hematoma: A case report and review of literature.

Taha MM, Elsharkawy AM, Al Menshawy HA, AlBakry A.

Surg Neurol Int. 2019 Dec 13;10:247. doi: 10.25259/SNI_543_2019. eCollection 2019.

2.

Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study.

Kamar N, Abravanel F, Behrendt P, Hofmann J, Pageaux GP, Barbet C, Moal V, Couzi L, Horvatits T, De Man RA, Cassuto E, Elsharkawy AM, Riezebos-Brilman A, Scemla A, Hillaire S, Donnelly MC, Radenne S, Sayegh J, Garrouste C, Dumortier J, Glowaki F, Matignon M, Coilly A, Figueres L, Mousson C, Minello A, Dharancy S, Rerolle JP, Lebray P, Etienne I, Perrin P, Choi M, Marion O, Izopet J; Hepatitis E Virus Ribavirin Study Group .

Clin Infect Dis. 2019 Dec 3. pii: ciz953. doi: 10.1093/cid/ciz953. [Epub ahead of print]

PMID:
31793638
3.

Hepatitis C Virus Epidemiology and the Impact of Interferon-Free Hepatitis C Virus Therapy.

Lazarus JV, Roel E, Elsharkawy AM.

Cold Spring Harb Perspect Med. 2019 Sep 30. pii: a036913. doi: 10.1101/cshperspect.a036913. [Epub ahead of print]

PMID:
31570385
4.

Predictive factors for 28-day mortality in acute-on-chronic liver failure patients admitted to the intensive care unit.

da Silva Boteon APC, Chauhan A, Boteon YL, Tillakaratne S, Gunson B, Elsharkawy AM, Ford A, Bangash M, Murphy N, Armstrong MJ, Rajoriya N, Perera MTPR.

Dig Liver Dis. 2019 Oct;51(10):1416-1422. doi: 10.1016/j.dld.2019.04.008. Epub 2019 May 4.

PMID:
31064706
5.

Aortic conduit aneurysm and enteric fistula formation in a post-liver transplant patient: A potential causative role for cytomegalovirus?

King D, Neil D, Forde C, Mirza D, Mergental H, Elsharkawy AM.

Transpl Infect Dis. 2019 Jun;21(3):e13092. doi: 10.1111/tid.13092. Epub 2019 Apr 25.

PMID:
30972849
6.

Home-Based Exercise in Patients Awaiting Liver Transplantation: A Feasibility Study.

Williams FR, Vallance A, Faulkner T, Towey J, Durman S, Kyte D, Elsharkawy AM, Perera T, Holt A, Ferguson J, Lord JM, Armstrong MJ.

Liver Transpl. 2019 Jul;25(7):995-1006. doi: 10.1002/lt.25442. Epub 2019 Jun 6.

PMID:
30859755
7.

Top research priorities in liver and gallbladder disorders in the UK.

Gurusamy KS, Walmsley M, Davidson BR, Frier C, Fuller B, Madden A, Masson S, Morley R, Safarik I, Tsochatzis EA, Ahmed I, Cowlin M, Dillon JF, Ellicott G, Elsharkawy AM, Farrington L, Glachan A, Kumar N, Milne EJ, Rushbrook SM, Smith A, Stafford L, Yeoman A.

BMJ Open. 2019 Mar 7;9(3):e025045. doi: 10.1136/bmjopen-2018-025045.

8.

Leaving behind pegylated interferon-based regimens to eliminate hepatitis C as a public health threat by 2030 as set out by WHO.

Lazarus JV, Pericàs JM, Elsharkawy AM.

Liver Int. 2018 Nov;38(11):1902-1905. doi: 10.1111/liv.13944. No abstract available.

PMID:
30358061
9.

The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations.

Lazarus JV, Safreed-Harmon K, Thursz MR, Dillon JF, El-Sayed MH, Elsharkawy AM, Hatzakis A, Jadoul M, Prestileo T, Razavi H, Rockstroh JK, Wiktor SZ, Colombo M.

Semin Liver Dis. 2018 Aug;38(3):181-192. doi: 10.1055/s-0038-1666841. Epub 2018 Jul 9. Review.

PMID:
29986353
10.

Toward Systematic Screening for Persistent Hepatitis E Virus Infections in Transplant Patients.

Ankcorn MJ, Ijaz S, Poh J, Elsharkawy AM, Smit E, Cramb R, Ravi S, Martin K, Tedder R, Neuberger J.

Transplantation. 2018 Jul;102(7):1139-1147. doi: 10.1097/TP.0000000000002097.

PMID:
29953421
11.

Balancing exercise-induced weight loss with protein caloric requirement remains a challenge in overweight patients with cirrhosis.

Dhaliwal A, Towey J, Haydon G, Elsharkawy AM, Armstrong MJ.

Hepatology. 2018 Apr;67(4):1644-1645. doi: 10.1002/hep.29801. Epub 2018 Feb 28. No abstract available.

PMID:
29357107
12.

Confirmation of specificity of reactivity in a solid phase ELISA for the detection of hepatitis E viral antigen improves utility of the assay.

Ankcorn MJ, Ijaz S, Haywood B, Neuberger J, Elsharkawy AM, Maggs J, Tedder RS.

J Virol Methods. 2018 Feb;252:42-48. doi: 10.1016/j.jviromet.2017.11.007. Epub 2017 Nov 20.

PMID:
29158182
13.

Hepatitis C Virus Recurrence Occurs Earlier in Patients Receiving Donation After Circulatory Death Liver Transplant Grafts Compared With Those Receiving Donation After Brainstem Death Grafts.

Townsend SA, Monga MA, Nightingale P, Mutimer D, Elsharkawy AM, Holt A.

Transplant Proc. 2017 Nov;49(9):2129-2134. doi: 10.1016/j.transproceed.2017.07.016.

PMID:
29149973
14.

Summary of the British Transplantation Society UK Guidelines for Hepatitis E and Solid Organ Transplantation.

McPherson S, Elsharkawy AM, Ankcorn M, Ijaz S, Powell J, Rowe I, Tedder R, Andrews PA.

Transplantation. 2018 Jan;102(1):15-20. doi: 10.1097/TP.0000000000001908.

PMID:
28795981
15.

Editorial: is ribavirin needed in the treatment of post-transplant hepatitis C recurrence?

Schmidt-Martin D, Elsharkawy AM.

Aliment Pharmacol Ther. 2017 Jul;46(2):197-198. doi: 10.1111/apt.14110. No abstract available.

16.

HIV-Positive-to-HIV-Positive Liver Transplantation.

Hathorn E, Smit E, Elsharkawy AM, Bramhall SR, Bufton SA, Allan S, Mutimer D.

N Engl J Med. 2016 Nov 3;375(18):1807-1809. No abstract available.

17.

Management of hepatitis C genotype 4 in the directly acting antivirals era.

Hathorn E, Elsharkawy AM.

BMJ Open Gastroenterol. 2016 Sep 30;3(1):e000112. eCollection 2016.

18.

Rescue from liver transplantation: TIPSS and thrombectomy successfully treat a case of acute Budd-Chiari syndrome complicated by portal vein thrombosis.

Townsend SA, Karkhanis S, Tripathi D, Mueisan P, Zia Z, Elsharkawy AM.

BJR Case Rep. 2016 Jul 27;3(1):20160059. doi: 10.1259/bjrcr.20160059. eCollection 2017.

19.

Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.

Fontana RJ, Brown RS Jr, Moreno-Zamora A, Prieto M, Joshi S, Londoño MC, Herzer K, Chacko KR, Stauber RE, Knop V, Jafri SM, Castells L, Ferenci P, Torti C, Durand CM, Loiacono L, Lionetti R, Bahirwani R, Weiland O, Mubarak A, ElSharkawy AM, Stadler B, Montalbano M, Berg C, Pellicelli AM, Stenmark S, Vekeman F, Ionescu-Ittu R, Emond B, Reddy KR.

Liver Transpl. 2016 Apr;22(4):446-58. doi: 10.1002/lt.24416.

20.

Changes in liver acceptance patterns after implementation of share 35.

Rajoriya N, Leithead JA, Elsharkawy AM, Gunson BK, Perera TM, Mutimer D.

Liver Transpl. 2016 Mar;22(3):375-6. doi: 10.1002/lt.24358. Epub 2016 Feb 15. No abstract available.

21.

Corrigendum: NFκB1 is a suppressor of neutrophil-driven hepatocellular carcinoma.

Wilson CL, Jurk D, Fullard N, Banks P, Page A, Luli S, Elsharkawy AM, Gieling RG, Bagchi Chakraborty J, Fox C, Richardson C, Callaghan K, Blair GE, Fox N, Lagnado A, Passos JF, Moore AJ, Smith GR, Tiniakos DG, Mann J, Oakley F, Mann DA.

Nat Commun. 2015 Sep 21;6:8411. doi: 10.1038/ncomms9411. No abstract available.

22.

NFκB1 is a suppressor of neutrophil-driven hepatocellular carcinoma.

Wilson CL, Jurk D, Fullard N, Banks P, Page A, Luli S, Elsharkawy AM, Gieling RG, Chakraborty JB, Fox C, Richardson C, Callaghan K, Blair GE, Fox N, Lagnado A, Passos JF, Moore AJ, Smith GR, Tiniakos DG, Mann J, Oakley F, Mann DA.

Nat Commun. 2015 Apr 16;6:6818. doi: 10.1038/ncomms7818. Erratum in: Nat Commun. 2015;6:8411.

23.

Is it time to revisit contraindications to organ donation from donors with a JAK-2 mutation? Safe use of a liver allograft from a donor with essential thrombocythaemia.

Haldar D, Chen F, Byron J, Elsharkawy AM, Perera MT.

Transpl Int. 2015 Jul;28(7):881-3. doi: 10.1111/tri.12558. Epub 2015 Mar 27.

24.

Is pentoxifylline still an option in severe alcoholic hepatitis?

Townsend SA, Rowe IA, Elsharkawy AM.

Hepatology. 2015 Nov;62(5):1643-4. doi: 10.1002/hep.27782. Epub 2015 May 12. No abstract available.

PMID:
25773475
25.

Fatigue in primary sclerosing cholangitis is associated with sympathetic over-activity and increased cardiac output.

Dyson JK, Elsharkawy AM, Lamb CA, Al-Rifai A, Newton JL, Jones DE, Hudson M.

Liver Int. 2015 May;35(5):1633-41. doi: 10.1111/liv.12709. Epub 2014 Dec 4.

26.

An 'alcohol contract' has no significant effect on return to drinking after liver transplantation for alcoholic liver disease.

Masson S, Marrow B, Kendrick S, Elsharkawy AM, Latimer S, Hudson M.

Transpl Int. 2014 May;27(5):475-81. doi: 10.1111/tri.12283. Epub 2014 Mar 15.

27.

Commentary: detection of low level viraemia in telaprevir-based triple therapy for hepatitis C virus.

Elsharkawy AM.

Aliment Pharmacol Ther. 2014 Mar;39(5):543-4. doi: 10.1111/apt.12610. No abstract available.

28.

Is the aerobic capacity at the time of cardiopulmonary exercise testing useful in predicting survival following liver transplantation?

Young R, Murphy N, Elsharkawy AM.

Liver Transpl. 2014 Apr;20(4):502. doi: 10.1002/lt.23840. Epub 2014 Feb 25. No abstract available.

29.

The etiology of intrahepatic cholestasis of pregnancy: towards solving a monkey puzzle.

Webb GJ, Elsharkawy AM, Hirschfield GM.

Am J Gastroenterol. 2014 Jan;109(1):85-8. doi: 10.1038/ajg.2013.437.

PMID:
24402531
30.

Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser.

Elsharkawy AM, Schwab U, McCarron B, Burt AD, Daly AK, Hudson M, Masson S.

J Clin Virol. 2013 Sep;58(1):331-3. doi: 10.1016/j.jcv.2013.05.003. Epub 2013 Jun 12.

PMID:
23763943
31.

Clinical and laboratory features and natural history of seronegative hepatitis in a nontransplant centre.

Donaghy L, Barry FJ, Hunter JG, Stableforth W, Murray IA, Palmer J, Bendall RP, Elsharkawy AM, Dalton HR.

Eur J Gastroenterol Hepatol. 2013 Oct;25(10):1159-64. doi: 10.1097/MEG.0b013e3283610484.

PMID:
23652914
32.

Improving access to treatment for patients with chronic hepatitis C through outreach.

Elsharkawy AM, Miller C, Hearn A, Buerstedde G, Price A, McPherson S.

Frontline Gastroenterol. 2013 Apr;4(2):125-129. doi: 10.1136/flgastro-2012-100282. Epub 2012 Dec 14.

33.

p38α inhibits liver fibrogenesis and consequent hepatocarcinogenesis by curtailing accumulation of reactive oxygen species.

Sakurai T, Kudo M, Umemura A, He G, Elsharkawy AM, Seki E, Karin M.

Cancer Res. 2013 Jan 1;73(1):215-24. doi: 10.1158/0008-5472.CAN-12-1602. Epub 2012 Dec 27.

34.

Multigenerational epigenetic adaptation of the hepatic wound-healing response.

Zeybel M, Hardy T, Wong YK, Mathers JC, Fox CR, Gackowska A, Oakley F, Burt AD, Wilson CL, Anstee QM, Barter MJ, Masson S, Elsharkawy AM, Mann DA, Mann J.

Nat Med. 2012 Sep;18(9):1369-77. Erratum in: Nat Med. 2012 Oct;18(10):1592.

35.

The future developments in hepatology: no need for a jaundiced view.

Elsharkawy AM, Hudson M.

Frontline Gastroenterol. 2012 Jul;3(Suppl 1):i47-i52. doi: 10.1136/flgastro-2012-100153. Epub 2012 May 31.

36.

Commentary: SOFA scores and staggered paracetamol overdose prognostication.

Elsharkawy AM, Mutimer DJ.

Aliment Pharmacol Ther. 2012 Jul;36(2):200-1; discussion 201-2. doi: 10.1111/j.1365-2036.2012.05149.x. No abstract available.

37.

[Cholestasis in young men after taking anabolic steroids].

Elsharkawy AM, McPherson S, Masson S, Burt A, Dawson RT, Hudson M.

Praxis (Bern 1994). 2012 May 9;101(10):661-4. doi: 10.1024/1661-8157/a000949. German. No abstract available.

PMID:
22565557
38.

Cholestasis secondary to anabolic steroid use in young men.

Elsharkawy AM, McPherson S, Masson S, Burt AD, Dawson RT, Hudson M.

BMJ. 2012 Feb 2;344:e468. doi: 10.1136/bmj.e468. No abstract available.

PMID:
22302781
39.

Use of a multilayered stent for the treatment of hepatic artery pseudoaneurysm after liver transplantation.

Elsharkawy AM, Sen G, Jackson R, Williams R, Rose J, Hudson M, Masson S, Manas DM.

Cardiovasc Intervent Radiol. 2012 Feb;35(1):207-10. doi: 10.1007/s00270-011-0335-3. No abstract available.

PMID:
22203063
40.

The NF-kappaB p50:p50:HDAC-1 repressor complex orchestrates transcriptional inhibition of multiple pro-inflammatory genes.

Elsharkawy AM, Oakley F, Lin F, Packham G, Mann DA, Mann J.

J Hepatol. 2010 Sep;53(3):519-27. doi: 10.1016/j.jhep.2010.03.025. Epub 2010 Jun 2.

41.

The c-Rel subunit of nuclear factor-kappaB regulates murine liver inflammation, wound-healing, and hepatocyte proliferation.

Gieling RG, Elsharkawy AM, Caamaño JH, Cowie DE, Wright MC, Ebrahimkhani MR, Burt AD, Mann J, Raychaudhuri P, Liou HC, Oakley F, Mann DA.

Hepatology. 2010 Mar;51(3):922-31. doi: 10.1002/hep.23385.

PMID:
20058312
42.

Wound healing and local neuroendocrine regulation in the injured liver.

Ebrahimkhani MR, Elsharkawy AM, Mann DA.

Expert Rev Mol Med. 2008 Apr 29;10:e11. doi: 10.1017/S146239940800063X. Review.

PMID:
18442446
43.

Hepatic nuclear factor kappa B regulates neutrophil recruitment to the injured brain.

Campbell SJ, Anthony DC, Oakley F, Carlsen H, Elsharkawy AM, Blomhoff R, Mann DA.

J Neuropathol Exp Neurol. 2008 Mar;67(3):223-30. doi: 10.1097/NEN.0b013e3181654957.

PMID:
18344913
44.

Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis.

Elsharkawy AM, Mann DA.

Hepatology. 2007 Aug;46(2):590-7. Review.

PMID:
17661407
45.

Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M.

Science. 2007 Jul 6;317(5834):121-4. Erratum in: Science. 2009 Dec 4;326(5958):1346.

46.

Todralazine hepatotoxicity: a sting in the histone tail.

Elsharkawy AM.

J Hepatol. 2007 Feb;46(2):189-92. Epub 2006 Dec 1. No abstract available.

PMID:
17161489
47.

Resolving fibrosis in the diseased liver: translating the scientific promise to the clinic.

Muddu AK, Guha IN, Elsharkawy AM, Mann DA.

Int J Biochem Cell Biol. 2007;39(4):695-714. Epub 2006 Oct 7. Review.

PMID:
17110155
48.

The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis.

Elsharkawy AM, Oakley F, Mann DA.

Apoptosis. 2005 Oct;10(5):927-39. Review.

PMID:
16151628
49.

Symptomatic cytomegalovirus infection complicating treatment of acute systemic vasculitis.

Elsharkawy AM, Perrin F, Farmer CK, Abbs IC, Muir P, Brown LJ, MacMahon EM, Goldsmith DJ.

Clin Nephrol. 2004 Oct;62(4):319-26. Review.

PMID:
15524064
50.

Supplemental Content

Loading ...
Support Center